Working… Menu

Treatment of Patients With the Obstructive Sleep Apnea Syndrome at Altitude

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00714740
Recruitment Status : Completed
First Posted : July 14, 2008
Last Update Posted : May 20, 2014
Information provided by (Responsible Party):
University of Zurich

Brief Summary:
The purpose of the study is to investigate the effect of acetazolamide as a treatment for sleep related breathing disturbances in patients with the obstructive sleep apnea syndrome living at low altitude during a sojourn at moderate altitude

Condition or disease Intervention/treatment Phase
Obstructive Sleep Apnea Syndrome Drug: acetazolamide Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 49 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Treatment of Patients With the Obstructive Sleep Apnea Syndrome at Altitude
Study Start Date : June 2008
Actual Primary Completion Date : December 2008
Actual Study Completion Date : December 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Sleep Apnea

Intervention Details:
  • Drug: acetazolamide
    acetazolamide 2 times 250mg per day
    Other Name: Diamox

Primary Outcome Measures :
  1. sleep disordered breathing, sleep structure, vigilance, subjective sleep quality acute mountain sickness [ Time Frame: during treatment while at altitude ]

Secondary Outcome Measures :
  1. blood pressure endothelial function [ Time Frame: during treatment while at altitude ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Obstructive sleep apnea syndrome, successfully on CPAP therapy
  • Residence at low altitude (<800m)
  • Obstructive apnea/hypopnea index >20/h and a complaint of excessive daytime sleepiness before introduction of CPAP therapy.
  • >15 oxygen desaturations/h (>3% dips) during an ambulatory nocturnal pulse oximetry performed at the end of a 4-night period without CPAP

Exclusion Criteria:

  • Sleep disorders other than OSA.
  • More than mild cardiovascular disease, unstable or recently diagnosed (within the last 6 months) cardiovascular disease such as arterial hypertension, coronary artery or cerebrovascular disease.
  • Any lung disease, pulmonary hypertension.
  • Chronic rhinitis.
  • Treatment with drugs that affect respiratory center drive (benzodiazepines or other sedatives or sleep inducing drugs, morphine or codeine derivates), stimulants (modafinil, methylphenidate, theophylline)
  • Internal, neurologic or psychiatric disease that interfere with sleep quality.
  • Previous intolerance to moderate or low altitude (<2600m).
  • Exposure to altitudes >1500m for >1 day within the last 4 weeks before the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00714740

Layout table for location information
Pulmonary Division, University Hospital Zurich
Zurich, Switzerland, CH-8091
Sponsors and Collaborators
University of Zurich
Layout table for investigator information
Study Director: Konrad E Bloch, MD Pulmonary Division, University Hospital Zurich, Switzerland
Layout table for additonal information
Responsible Party: University of Zurich Identifier: NCT00714740    
Other Study ID Numbers: EK-1522
First Posted: July 14, 2008    Key Record Dates
Last Update Posted: May 20, 2014
Last Verified: May 2014
Keywords provided by University of Zurich:
apnea, sleep, altitude, hypoxia
Additional relevant MeSH terms:
Layout table for MeSH terms
Sleep Apnea Syndromes
Sleep Apnea, Obstructive
Pathologic Processes
Respiration Disorders
Respiratory Tract Diseases
Signs and Symptoms, Respiratory
Sleep Disorders, Intrinsic
Sleep Wake Disorders
Nervous System Diseases
Carbonic Anhydrase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Natriuretic Agents
Physiological Effects of Drugs